Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Dystrophic Epidermolysis Bullosa Clear all
Recruiting Phase 2 Interventional

Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin

NCT06731933
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
BVEC
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Redwood City, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Active, not recruiting No phase listed Observational

Artificial Intelligence Patient App for RDEB SCCs

NCT05843994
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
online survey
Other
Lead sponsor
Northwestern University
Other
Eligibility
12 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Completed No phase listed Observational

Short Term Observational Study in DEB Patients

NCT02178969
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT03752905
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
PTR-01, Normal saline
Drug
Lead sponsor
Phoenix Tissue Repair, Inc.
Industry
Eligibility
16 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Redwood City, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting No phase listed Observational

A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

NCT07700966
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Prademagene Zamikeracel
Combination Product
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
Not listed
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
4
States / cities
Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated No phase listed Observational

Recessive Dystrophic Epidermolysis Bullosa Screening for Possible Gene Transfer

NCT00533572
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Jul 23, 2026, 11:41 PM EDT
Enrolling by invitation No phase listed Observational

A Long-Term Extension Study for Participants Previously Treated With EB-101 for the Treatment of RDEB

NCT05708677
View directory record Official record
Conditions
RDEB
Interventions
EB-101
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting No phase listed Observational

Long-Term Follow-up Protocol

NCT04917887
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Not listed
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
6 Months and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
3
States / cities
Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Jul 23, 2026, 11:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

MSC EVs in Dystrophic Epidermolysis Bullosa

NCT04173650
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
AGLE-102
Drug
Lead sponsor
Aegle Therapeutics
Industry
Eligibility
6 Months and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Phoenix, Arizona • Los Angeles, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 3 Interventional Results available

Open Label Extension Study to Evaluate the Long-term Safety of Zorblisa (SD-101-6.0) in Patients With Epidermolysis Bullosa

NCT02670330
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101-6.0 cream
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
1 Month and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2019 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Not applicable Interventional Results available

Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa

NCT00478244
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
busulfan, cyclophosphamide, fludarabine phosphate, hematopoietic bone marrow transplantation
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 25 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional

A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa

NCT04599881
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
PTR-01
Drug
Lead sponsor
Phoenix Tissue Repair, Inc.
Industry
Eligibility
12 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Redwood City, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Jul 23, 2026, 11:41 PM EDT
Completed No phase listed Observational

Characteristics of Adult Patients With Recessive Dystrophic Epidermolysis Bullosa

NCT00904163
View directory record Official record
Conditions
Epidermolysis Bullosa Dystrophica
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 3 Interventional Results available

ESSENCE Study: Efficacy and Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

NCT02384460
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101-6.0 cream, Placebo (SD-101-0.0) cream
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
1 Month and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
21
States / cities
Phoenix, Arizona • Redwood City, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Apligraf in Nonhealing Wounds of Subjects With Junctional or Dystrophic Epidermolysis Bullosa (EB)

NCT00587223
View directory record Official record
Conditions
Epidermolysis Bullosa, Junctional, Epidermolysis Bullosa Dystrophica
Interventions
Apligraf, Standard dressing regimen
Device · Other
Lead sponsor
Organogenesis
Industry
Eligibility
2 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
5
States / cities
Stanford, California • Miami, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2010 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 3 Interventional

A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

NCT04917874
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa, DEB - Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa, Dominant Dystrophic Epidermolysis Bullosa
Interventions
Open Label Topical Beremagene Geperpavec (B-VEC)
Biological
Lead sponsor
Krystal Biotech, Inc.
Industry
Eligibility
2 Months and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Rancho Santa Margarita, California • Redwood City, California • Coral Gables, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2024 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 2 Interventional Results available

Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa

NCT02090283
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (6%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Early Phase 1 Interventional

Characterization of the Microbiome in Colonized Dystrophic and Junctional Epidermolysis Bullosa Wounds Before and After Use of APR-TD011 ® Spray Solution

NCT05533866
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
APR-TD011
Combination Product
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 23, 2026, 11:41 PM EDT
Active, not recruiting Phase 3 Interventional

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

NCT06892639
View directory record Official record
Conditions
Dystrophic Epidermolysis Bullosa
Interventions
D-Fi
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
2 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2042
U.S. locations
4
States / cities
Redwood City, California • Santa Margarita, California • Aurora, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Effectiveness and Safety of SD-101 in Participants With Epidermolysis Bullosa

NCT02014376
View directory record Official record
Conditions
Epidermolysis Bullosa
Interventions
SD-101 dermal cream (3%), SD-101 Dermal Cream (6%), Vehicle (SD-101 0%)
Drug
Lead sponsor
Scioderm, Inc.
Industry
Eligibility
6 Months and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
7
States / cities
Palo Alto, California • Chicago, Illinois • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 1 Interventional Results available

To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB)

NCT03472287
View directory record Official record
Conditions
Epidermolysis Bullosa (EB), Epidermolysis Bullosa Simplex, Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Interventions
Diacerein 1% Ointment
Drug
Lead sponsor
Castle Creek Pharmaceuticals, LLC
Industry
Eligibility
4 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Palo Alto, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Jul 23, 2026, 11:41 PM EDT
Not listed Phase 1Phase 2 Interventional

Intravenous Gentamicin Therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT03392909
View directory record Official record
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Gentamicin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
7 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Jul 23, 2026, 11:41 PM EDT
Completed Phase 3 Interventional

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT04227106
View directory record Official record
Conditions
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions
EB-101
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
6 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Jul 23, 2026, 11:41 PM EDT
Terminated Phase 2 Interventional

Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa

NCT03578029
View directory record Official record
Conditions
Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Interventions
RGN-137, Placebo
Drug
Lead sponsor
Lenus Therapeutics, LLC
Industry
Eligibility
4 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Evanston, Illinois • Brooklyn, New York • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2022 · Synced Jul 23, 2026, 11:41 PM EDT